All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., priced an underwritten public offering of 17.5 million common shares and warrants to purchase another 17.5 million common shares at a price of 75 cents for a fixed unit of one common share plus a warrant to purchase an additional common share.